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Introduction: Orbital metastases of lung cancer are rare. However, because the number of patients diagnosed with
lung cancer is increasing, the probability that a physician will see a patient with an orbital metastasis is also
increasing. Unfortunately, the clinical course and response of these patients to cytotoxic chemotherapy are
generally poor and keeping a patient’s quality of vision is difficult. In recent years, gefitinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, has brightened the outlook for patients with advanced non-small cell lung
cancer, especially for those who carry epidermal growth factor receptor-activating mutations.
Case presentation: A 62-year-old Japanese man presented with swelling of the eyelid margin and ptosis of his right
eye. A physical examination revealed double vision in his right eye and an alteration in elevator muscle mobility.
A magnetic resonance image demonstrated a right intra-orbital mass (18 × 16mm). Screening examinations were
carried out because this mass was suspected to be a metastasis from another organ. Chest computed tomography
revealed a 42 × 37mm mass shadow on the left side of the hilum with mediastinal lymph node metastases.
Adenocarcinoma with an epidermal growth factor receptor gene mutation (exon 19 deletion L747-E749; A750P) was
detected in a transbronchial biopsy specimen; the patient was diagnosed with stage IV (T2N2M1) non-small cell lung
cancer.
Gefitinib (250mg/day) was chosen as first-line chemotherapy because there was no pre-existing interstitial shadow.
After two months of treatment, the patient’s right eye opened completely and follow-up magnetic resonance
imaging revealed a marked reduction of the intra-orbital mass to 14 × 13mm. Three months after treatment
initiation, a follow-up computed tomography showed a marked reduction in the size of the primary lesion to 23 ×
20mm. The patient is continuing gefitinib treatment without any adverse effects noted on computed tomography,
physical, or laboratory examination.
Conclusions: We report the case of a patient with an orbital non-small cell lung cancer metastasis with epidermal
growth factor receptor-activating mutations. This metastasis, as well as the primary lesion, showed a marked
response to the molecular targeting drug gefitinib, and the patient’s vision was kept without an invasive procedure.
Gefitinib may be a good first choice for patients with orbital non-small cell lung cancer metastasis harboring
epidermal growth factor receptor-activating mutations.Introduction
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Figure 1 Brain magnetic resonance image. A: Showing an intra-orbital mass on the right side before gefitinib therapy. B: Revealing a
reduction of the intra-orbital mass after two months of gefitinib therapy.
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cacy of gefitinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, compared with that of
combination cytotoxic chemotherapy in patients with
EGFR-activating mutations [3]. To the best of our know-
ledge, no report has published the effect of gefitinib on an
orbital metastasis.
Here we present the case of a patient with orbital me-
tastasis of lung adenocarcinoma which showed a good
response to gefitinib therapy in both the primary lesion
and orbital metastasis improving the patient’s quality of
vision.
Case presentation
A 62-year-old Japanese man presented with swelling of
the eyelid margin and ptosis of his right eye. He was a
heavy cigarette smoker (30 cigarettes per day for 50
years). He had no other significant medical history. A
physical examination revealed double vision in the right
eye and an alteration in elevator muscle mobility. The
patient’s visual acuity was not reduced; there was no
increased intra-ocular pressure.
A magnetic resonance image (MRI) demonstrated a
right intra-orbital mass (18 × 16mm; Figure 1A) with
bone destruction at the left temporal bone (figure not
shown). Screening examinations were carried out because
this mass was suspected to be a metastasis from another
organ. Chest computed tomography (CT) revealed a 42 ×Figure 2 Chest computed tomography images. A: Showing a mass sha
a good response of the primary tumor after three months of gefitinib thera37mm mass shadow on the left side of the hilum with me-
diastinal lymph node metastases (Figure 2A). Adenocarcin-
oma with an EGFR gene mutation (exon 19 deletion L747-
E749; A750P) was detected in a transbronchial biopsy
specimen; the patient was diagnosed with stage IV
(cT2N2M1b) non-small cell lung cancer (NSCLC).
The tumor marker carcinoembryonic antigen (CEA)
was elevated to 71.2ng/mL (normal range <5ng/mL).
Gefitinib (250mg/day) was chosen as the first-line
chemotherapy because there was no pre-existing intersti-
tial shadow. The patient’s ptosis slightly improved after
two weeks of therapy; after two months of treatment his
right eye opened completely and exhibited improved mo-
bility. Follow-up MRI revealed a marked reduction of the
intra-orbital mass to 14 × 13mm (Figure 1B). Three
months after treatment initiation, a follow-up CT showed
a marked reduction in the size of the primary lesion to
23 × 20mm (Figure 2B). In addition, CEA decreased to
5.5ng/mL. The patient is continuing gefitinib treatment
without any adverse effects noted on CT, physical, or la-
boratory examination.
Discussion
Orbital metastases have been reported to originate in
many organs. No matter from where the primary lesion
originates, orbital metastases generally lead to an alter-
ation in ocular motility, and proptosis due to an increase
in intra-orbital volume that reduces vision [4]. Of casesdow on the left side of the hilum before gefitinib therapy. B: Revealing
py.
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nerve, 20% showed a reduction in vision [5].
Because treating an orbital metastasis is not a complete
cure, therapy targeting the primary lung cancer must
take precedence. Sometimes an invasive procedure,
radiotherapy and orbital surgery may be undertaken to
relieve the patient’s pain or because the patient’s vision is
important to their quality of life [1].
The number of patients diagnosed with lung cancer
is increasing and because the lung is one of the most
frequent reported origins of orbital metastases, the
probability that a physician will see a patient with an
orbital metastasis is also increasing. The most frequent
pathological types are adenocarcinoma (65%) and more
than half of them are of the poorly differentiated type [2].
The EGFR mutation rate of cases with orbital metastases
is unknown.
The choice of a systemic therapy agent for stage IV
lung cancer with metastases depends on the histological
type of the primary tumor. In small cell lung cancer
(SCLC), cytotoxic chemotherapy (usually a platinum-
based combination therapy) is effective for orbital metas-
tases as well as for the primary lesion. Unfortunately,
cytotoxic chemotherapy does not show as quick a re-
sponse for NSCLC as it does for SCLC. Recently, several
novel antitumor agents have brightened the outlook for
patients with advanced NSCLC; in fact, Zarogoulidis
et al. reported favorable efficacy of combination chemo-
therapy including bevacizumab and pemetrexed in
patients with orbital metastasis [6]. Gefitinib shows a
rapid and improved response rate over combination
chemotherapy in patients with NSCLC harboring EGFR-
activating mutations [3]. The efficacy of gefitinib could
be expected to apply not only to the primary lesion, but
also to metastatic lesions. This case showed the efficacy
of gefitinib to orbital metastasis with high response rate.
Thus, the patient’s quality of vision could be saved with-
out an invasive procedure. Unfortunately, however,
patients usually acquire resistance to gefitinib around 12
months of treatment [3]. Further studies will be needed
to elucidate the efficacy of gefitinib on metastasis.Conclusion
Here we present the case of a patient with orbital metas-
tasis of lung adenocarcinoma in which a marked positive
response to gefitinib therapy was shown in both the pri-
mary lesion and orbital metastasis. Gefitinib therapy
improved the patient’s quality of vision without an inva-
sive procedure. Patients with orbital metastases are in
need of highly effective treatment if their vision is to be
spared; gefitinib may be a good first choice for patients
with NSCLC and EGFR-activating mutations.Consent
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